EGFR and neoplasm: Consistent with this concept, among our nine evaluable patients who harbored EGFR amplification by cfDNA analysis, anti-EGFR–based therapies led to tumor reduction in 66.7% (six of nine) including 55.6% (five of nine) who achieved a PR (Fig 4).